Abstract:BackgroundInhibition of sphingosine kinase 1 (SphK1), which catalyzes bioactive lipid sphingosine-1–phosphate (S1P), attenuates NLRP3 inflammasome activation. S1P exerts most of its function by binding to S1P receptors (S1PR1-5). The roles of S1P receptors in NLRP3 inflammasome activation remain unclear.Materials and methodsThe mRNA expressions of S1PRs in bone marrow-derived macrophages (BMDMs) were measured by real-time quantitative polymerase chain reaction (qPCR) assays. BMDMs were primed with LPS and stimulated with NLRP3 activators, including ATP, nigericin, and imiquimod. Interleukin-1β (IL-1β) in the cell culture supernatant was detected by enzyme-linked immunosorbent assay (ELISA). Intracellular potassium was labeled with a potassium indicator and was measured by confocal microscopy. Protein expression in whole-cell or plasma membrane fraction was measured by Western blot. Cecal ligation and puncture (CLP) was induced in C57BL/6J mice. Mortality, lung wet/dry ratio, NLRP3 activation, and bacterial loads were measured.ResultsMacrophages expressed all five S1PRs in the resting state. The mRNA expression of S1PR3 was upregulated after lipopolysaccharide (LPS) stimulation. Inhibition of S1PR3 suppressed NLRP3 and pro-IL-1β in macrophages primed with LPS. Inhibition of S1PR3 attenuated ATP-induced NLRP3 inflammasome activation, enhanced nigericin-induced NLRP3 activation, and did not affect imiquimod-induced NLRP3 inflammasome activation. In addition, inhibition of S1PR3 suppressed ATP-induced intracellular potassium efflux. Inhibition of S1PR3 did not affect the mRNA or protein expression of TWIK2 in LPS-primed BMDMs. ATP stimulation induced TWIK2 expression in the plasma membrane of LPS-primed BMDMs, and inhibition of S1PR3 impeded the membrane expression of TWIK2 induced by ATP. Compared with CLP mice treated with vehicle, CLP mice treated with the S1PR3 antagonist, TY52156, had aggravated pulmonary edema, increased bacterial loads in the lung, liver, spleen, and blood, and a higher seven-day mortality rate.ConclusionsInhibition of S1PR3 suppresses the expression of NLRP3 and pro-IL-1β during LPS priming, and attenuates ATP-induced NLRP3 inflammasome activation by impeding membrane trafficking of TWIK2 and potassium efflux. Although inhibition of S1PR3 decreases IL-1β maturation in the lungs, it leads to higher bacterial loads and mortality in CLP mice.

Chronic TLR Stimulation Controls NLRP3 Inflammasome Activation Through IL-10 Mediated Regulation of NLRP3 Expression and Caspase-8 Activation

Phosphodiesterase 4B is Required for NLRP3 Inflammasome Activation by Positive Feedback with Nrf2 in the Early Phase of LPS- Induced Acute Lung Injury

TLR agonists stimulate Nlrp3-dependent IL-1β production independently of the purinergic P2X7 receptor in dendritic cells and in vivo.

Regulation of NLRP3 Inflammasome by Phosphorylation

TLR‐induced NF‐κB Activation Regulates NLRP3 Expression in Murine Macrophages

Regulation of the NLRP3 inflammasome by autophagy and mitophagy

Recent Insights into the Regulatory Networks of NLRP3 Inflammasome Activation

The Signaling Pathways Regulating NLRP3 Inflammasome Activation

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules

Inhibition of Sphingosine-1-phosphate Receptor 3 Suppresses ATP-induced NLRP3 Inflammasome Activation in Macrophages Via TWIK2-mediated Potassium Efflux

Activation and Regulation of NLRP3 by Sterile and Infectious Insults

Lipopolysaccharide promotes NLRP3 inflammasome activation by inhibiting TFEB-mediated autophagy in NRK-52E cells

Modulatory mechanisms of NLRP3: Potential roles in inflammasome activation

AKT Controls NLRP3 Inflammasome Activation by Inducing DDX3X Phosphorylation

The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation

Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases

Pharmacological Inhibitors of the NLRP3 Inflammasome

Cutting Edge: Nitric Oxide Inhibits the NLRP3 Inflammasome.

Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia

p38 MAPK Activity Is Required to Prevent Hyperactivation of NLRP3 Inflammasome